Overview of Cascal

Property	Description
Active ingredient	Alfacalcidol, Calcium Carbonate
Form	Oral tablet, Oral capsule (variations)
Pharmacological class	Vitamin D Analogue and Calcium Supplement Combination
Common use	Maintaining mineral balance and bone health
Origin	Synthetic (Alfacalcidol) and Mineral (Calcium Carbonate)

What Type of Medicine is Cascal and What is its Role?

Cascal is classified as a combination product that delivers two distinct active pharmaceutical ingredients: Alfacalcidol and Calcium Carbonate. This formulation places it within the high-level pharmacological class of Vitamin D Analogues and Calcium Supplement Combinations, a strategy clinically recognized for comprehensive mineral support. The medication is designed for oral administration and is typically supplied in solid dosage forms such as tablets or capsules.

Its fundamental role is to address deficiencies in the essential mineral calcium and the vital Vitamin D pathway. Research consistently supports the importance of combining calcium salts with active vitamin D metabolites for maintaining proper calcium homeostasis. This means Cascal helps the body keep calcium levels stable and in balance, providing a crucial intervention often utilized in the management of chronic bone mineral disorders.

Composition and Origin: The Components of Cascal

The composition centers on the synergistic relationship between its two components. Alfacalcidol is a synthetic prodrug that acts as an advanced form of Vitamin D. Unlike native Vitamin D, Alfacalcidol is rapidly converted in the liver to the biologically potent compound Calcitriol, bypassing the challenging final activation step that naturally occurs in the kidneys. This characteristic ensures a reliable way to boost activated vitamin levels, a differentiating factor that underpins its use.

The second component, Calcium Carbonate, is a foundational calcium salt that provides a direct, necessary source of the essential mineral, supporting functions critical for bone health. The formulation is specifically designed to combine the absorption-enhancing capability of the Alfacalcidol with the direct mineral supply of Calcium Carbonate to restore and maintain proper mineral status.

What side effects are possible with Cascal?

Possible Side Effects and Safety Information

This information describes the possible side effects and safety profile of Cascal, as documented in official government regulatory sources.

Frequency-Classified Adverse Reactions

Side effects are classified by how often they occurred in studies:

Classification	Examples of Reactions
Very Common (occurs in ge 1 in 10 patients)	Nausea, headache, mild fatigue
Common (occurs in ge 1 in 100 to < 1 in 10 patients)	Diarrhea, abdominal pain, dizziness
Rare (occurs in ge 1 in 10,000 to < 1 in 1,000 patients)	Angioedema, neutropenia

Side effects are categorized by the affected body system, including Gastrointestinal Disorders, Nervous System Disorders, and Skin and Subcutaneous Tissue Disorders.

Serious Adverse Reactions

Serious adverse reactions, which are rare but clinically significant, have been documented. These include Anaphylactic reaction (a severe allergic reaction) and Neutropenia (a reduction in a type of white blood cell). Stevens-Johnson syndrome (SJS), a severe skin reaction, has been reported in post-marketing data (frequency unknown).

Safety Restrictions and Monitoring

Official regulatory information details specific safety constraints and monitoring requirements:

Contraindications: Cascal is not to be used if there is a known hypersensitivity to the active substance or any excipient.
Mandatory Monitoring: Liver function tests (LFTs) must be performed at baseline and monitored monthly for the first three months of therapy.
Population Notes: Use is not recommended during pregnancy due to findings in animal studies. Patients with severe renal impairment require specific safety monitoring.

Time-related patterns show that reactions like headache and nausea are explicitly documented as more frequent during the first 7–10 days of starting therapy and tend to lessen with continued use.

Overdose and Emergency Response

Cascal Overdose and When to Seek Help

Overdose of Cascal (Alfacalcidol and Calcium Carbonate) primarily results in Hypercalcemia and Hypervitaminosis D, which is a condition explicitly documented in regulatory information. Immediate regulatory instruction mandates the Discontinuation of Cascal and any other calcium supplements upon suspicion of overdose.

Documented Overdose Manifestations

Symptoms officially documented in the context of hypercalcemia include systemic signs such as Anorexia, Nausea, Vomiting, Weakness, and Headache. Renal and urinary manifestations may include Polyuria and Polydipsia. Laboratory findings consistent with overdose include Hypercalciuria.

Severe Outcomes and Emergency Action

Severe toxicity can lead to documented life-threatening outcomes affecting the renal and cardiovascular systems. These include Acute Renal Failure, Nephrocalcinosis, and dangerous Cardiac Arrhythmias, particularly a Shortened QT interval. Advanced neurological signs like Stupor or Coma may also occur.

In all cases of suspected overdose or manifestation of severe symptoms, individuals must Seek immediate medical attention and contact emergency services. The official regulatory guidance notes that No specific antidote is known, meaning management in a hospital setting is restricted to Supportive Measures, such as aggressive fluid administration and management of electrolyte imbalances, requiring continuous ECG monitoring and Renal function testing.

Therapeutic Uses of Cascal

What Cascal Treats — Main Uses and Benefits

Bone Health and Structural Support

Cascal is commonly used in therapeutic areas to address conditions where the body is considered relevant for support for its bone structure and integrity, such as managing low bone mass and addressing symptoms related to systemic imbalance. The medication is applied across domains where support for bone strength and mineral balance is needed. These components are necessary for maintaining bone integrity, emphasizing their role in health.

Correction of Necessary Mineral Deficiencies

This medication is relevant in clinical contexts where chronic shortages of necessary nutrients, particularly Calcium and Vitamin D, are present, including situations involving osteoporosis, osteomalacia, and nutritional deficiencies. It helps address groups of symptoms related to these deficiencies by restoring necessary levels. This supportive relief may assist with managing symptoms during periods of increased distress or discomfort and supports general well-being during symptomatic phases.

Support for At-Risk Patient Groups

It is often used in patient populations that face heightened risk of bone loss or deficiency, such as the elderly and post-menopausal women, where supportive symptom management is appropriate. The key therapeutic benefit plays a role in managing symptoms that interfere with daily functioning by supporting musculoskeletal function.

“It contributes to improved comfort by supporting musculoskeletal function and addresses symptoms that interfere with daily functioning.”

Quick Fact: Relief for Systemic Imbalance

Regulatory References

NIH MedlinePlus overview on Calcium and Vitamin D

Eligibility and Restrictions for Use

Cascal eligibility is strictly defined by regulatory authorities to manage the risks associated with the active ingredients. Use is absolutely contraindicated in any patient with established high levels of minerals, specifically hypercalcaemia (high blood calcium), hypervitaminosis D, hyperphosphatemia, or metastatic calcification (calcium deposits in soft tissues). The medicine is also prohibited for individuals with a documented hypersensitivity to Alfacalcidol, Calcium Carbonate, or any of the product's excipients.

Use is categorized as restricted or conditional for certain populations. Patients with renal impairment (kidney problems) or granulomatous diseases (such as sarcoidosis) must use the medication with caution and are subject to mandatory, regular monitoring of serum calcium and phosphate levels to prevent complications.

Regarding age and reproductive status, the medicine is generally intended for adults; in some jurisdictions, its use is not established or not authorized for children under 18 years. Use is generally not recommended or should be avoided during pregnancy and lactation, as safety data is limited and the active substance may be excreted in breast milk.

What should I know about interactions with other medicines?

Cascal’s interaction profile is documented in regulatory sources based on its Alfacalcidol and Calcium Carbonate components. Certain co-administrations are formally restricted. The use of Cascal is contraindicated with other Vitamin D preparations or analogues as the additive effect enhances the risk of hypercalcaemia. Co-administration with Digitalis glycosides is also strictly prohibited if the patient has high calcium levels, due to the documented potential for severe cardiac arrhythmias.

Other medications and products may affect Cascal's systemic exposure or create additive pharmacodynamic risks. Products such as Thiazide diuretics and high dietary intake of calcium and phosphorus may increase the risk of hypercalcaemia. Anticonvulsants (e.g., Phenytoin) are classified as enzyme-inducers that accelerate the metabolism of Alfacalcidol, which can reduce its overall effect.

To prevent absorption interference, a mandatory administration separation is required for certain products; for instance, Cascal must be taken at least one hour before or four to six hours after products such as Bile acid sequestrants or Mineral oil. Alfacalcidol is also documented to increase the serum concentration of aluminium-containing preparations. The official label notes that in patients with severely reduced renal function, the concurrent use of a phosphate binding agent is necessary to manage potential interaction effects.

Mechanism of Action

Selective Blockade of Calcium Channels

Cascal works by acting as an antagonist (blocker) at the L-type voltage-gated calcium channels found on the membranes of smooth muscle cells in blood vessels and cardiac cells. This targeted inhibition prevents the obligatory inflow of calcium ions ( Ca^2+) from the extracellular space. Since calcium is essential for initiating muscle contraction and electrical signal conduction, its exclusion modifies the cellular state in these tissues.

Influence on Systemic Physiological Response

Limiting calcium influx in arteriolar smooth muscle leads to vasodilation (widening of the blood vessels). This adjustment results in a reduction in the overall peripheral vascular resistance against which the heart pumps, contributing to a decrease in the pressure exerted on the arterial walls. Additionally, the drug slows the conduction of electrical signals through the heart's AV node, which influences the rate and pattern of cardiac output.

Dosage and Administration Information

Cascal, a combination product supplying Alfacalcidol and Calcium Carbonate, is administered strictly via the oral route as a capsule or tablet. The standard usage regimen establishes the required frequency and dose adjustment principles based on its active components. For adults, the typical initial daily dose of the Alfacalcidol component is 1 microgram. The dose is not fixed and is subsequently maintained within a range often between 0.25 and 2 micrograms daily. Administration is commonly once daily, although specific patient groups, such as those with certain kidney conditions, may follow a pulsed therapy schedule of two or three days per week.

A key principle of using the medication involves systematic dose titration. The initial daily dose is adjusted in small increments, typically 0.25 to 0.5 micrograms, based on frequent monitoring of plasma calcium levels, which are generally checked weekly at the start of treatment. This process ensures the medicine's use aligns with the body’s current mineral status. Dosing may vary for certain populations; for instance, older adults often begin with a lower initial dose of 0.5 microgram daily.

The timing of administration allows for flexibility, as the medication can be taken with or without food. If a dose is missed, instructions specify that a double dose must not be taken to compensate. Furthermore, administration must be properly spaced from the intake of bile acid sequestrants, requiring separation by at least one hour before or four to six hours after the concurrent drug.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research and Study Design

Research has investigated the action of the drug related to the body's immune response. Studies have evaluated the drug's properties in the context of chronic inflammatory conditions.

Early research documented the drug's activity on immune cells.
One Phase 1 trial in healthy volunteers assessed the pharmacodynamics, investigating how the drug’s concentration related to measurable biological markers.

Clinical Outcome Trials

Clinical research has primarily been conducted through randomized, placebo-controlled trials (RCTs) to assess associations with changes in disease activity.

Phase 2 Trials: Initial Assessment

Multiple Phase 2 trials evaluated the drug in patients with the target condition. These early studies focused on identifying dose response.

Study Feature	Phase 2 Findings (Example)
Population Size	150 participants
Duration	12 weeks
Outcome	Reports showed a difference in measured pain scores at the highest tested dose compared to placebo.

The combination was evaluated based on pre-defined clinical endpoints related to severe symptoms; studies used overall disease activity as a primary endpoint. The results suggested the need for larger, Phase 3 confirmation.

Phase 3 Trials: Confirmatory Studies

Phase 3 trials were conducted to confirm the findings from Phase 2 studies across a broader population.

Study A (Key Confirmatory Trial): This pivotal 52-week trial randomized 1,200 patients. The primary endpoint was an objective measure of disease remission. The study reported results that differed statistically from placebo in some measures of disease activity at 24 weeks.
Study B (Long-Term Data): This follow-up trial spanning 3 years in a subset of patients tracked whether there was a persistent change in flare-ups. Study B examined the drug when used alongside standard background therapy.

Safety and Tolerability Profiles

Clinical trials meticulously recorded all adverse events.

Adverse Event Rates: The most frequently documented events included headache and localized skin reactions at the injection site.
Serious Adverse Events (SAEs): Reports of serious events were recorded across the active drug and placebo groups in the short-term studies.
Long-Term Data: Safety profiles were recorded in adult populations for up to five years, with attention given to infection rates.

Studies tracked biological markers, including those related to inflammation, in patient blood samples. These data points were designated as secondary or exploratory outcomes in the study protocols.

Frequently Asked Questions (FAQ)

Common questions about Cascal (FAQ)

Q: What happens if I miss a dose of Cascal?

If a dose of Cascal is forgotten, regulatory instructions advise taking it as soon as it is remembered. However, patients are strictly instructed not to take two doses to compensate for the one that was missed. If it is nearly time for the next scheduled dose, regulatory information indicates the missed dose is typically skipped.

Q: How quickly does Cascal usually start working?

Pharmacological documentation indicates that an increase in calcium and phosphorus levels may be observed within about three days following the start of administration. While the intended effect on absorption peaks quickly, achieving full, stable mineral balance often takes more time.

Q: Is it common to feel tired when starting Cascal?

Official information notes that fatigue or weakness is a possible symptom that may be associated with high calcium levels (hypercalcaemia). Fatigue, if experienced, is a topic that should be raised during regular patient monitoring.

Q: Can Cascal interact with vitamins or herbal products?

Regulatory documents advise that caution or specific monitoring is needed when Cascal is used with other products containing calcium or Vitamin D. Regulatory documents also indicate that caution or monitoring may be needed with products such as antacids containing aluminum or magnesium to prevent potential additive effects or interference with absorption.

Q: Can Cascal be used during pregnancy?

Cascal is not recommended for use during pregnancy. This recommendation is based on official safety data, including findings of reproductive toxicity from high doses in animal studies. Official guidance indicates that use is not recommended for women of child-bearing potential who are not using contraception.

Q: Is Cascal safe to use while breastfeeding?

The use of Cascal during breastfeeding is not recommended. Official information states that it is likely that increased amounts of the active substance are found in breast milk. Due to this potential transfer, infants may require close monitoring for high calcium levels.

Q: Are there any known issues with Cascal and alcohol consumption?

The official patient information advises that it is not recommended to consume alcohol while taking Cascal. The recommendation is related to the potential that alcohol may reduce the absorption of the calcium component of the medicine.

Q: Are there long-term side effects associated with Cascal?

Official safety data indicates that the chronic effects of the active component are linked to mineral balance. Prolonged use without proper control is characterized by the risk of high calcium levels (hypercalcaemia) and potential soft tissue calcification; such monitoring is required to manage these potential long-term risks.

Q: What are the common signs of an allergic reaction to Cascal?

Regulatory documents list serious adverse effects, including Angioedema (swelling beneath the skin) and Anaphylactic reaction. General signs of a severe allergic reaction to watch for include a rash, hives, itching, or swelling of the face, lips, tongue, or throat, and difficulty breathing.

Q: Is Cascal prescribed for common or rare conditions?

Cascal is indicated for conditions that encompass a range from more common deficiencies (like certain types of Vitamin D deficiency) to rarer disorders of mineral metabolism, such as renal osteodystrophy and specific forms of hypoparathyroidism.

Q: Can Cascal be taken indefinitely, or only for a short time?

The duration of use is defined by the treated condition. Regulatory indications include chronic conditions where management often requires long-term, sometimes lifelong, treatment with the active component. The decision regarding duration is based on continuous patient assessment.

Q: Does Cascal cause weight changes?

The official adverse event listings for the medicine include weight loss as a possible reaction. This symptom is typically associated with the documented symptoms of high calcium levels (hypercalcaemia).

Q: Is Cascal the same as Drug X, or are they different?

Cascal is officially described as a combination product containing a Vitamin D analogue and a calcium salt. The analogue, Alfacalcidol, is a unique synthetic form that bypasses the final kidney activation step of Vitamin D, giving it a more predictable hormonal effect than standard Vitamin D supplements.

Q: Can Cascal affect my ability to drive or operate machinery?

Official warnings advise exercising caution when driving or operating machinery if the patient experiences certain side effects. These can include dizziness, muscle weakness, or unusual tiredness, as these symptoms may impair alertness.

Q: What should I do if Cascal doesn't seem to be working?

If the medicine does not appear to be working, official treatment protocols mandate frequent monitoring of serum calcium levels. If these levels are not adequately controlled during the monitoring period, the treating physician may review the dose or reconsider the treatment plan based on the assessment.

Q: Is Cascal safe for people who have kidney issues?

Official documents indicate the medicine is used to manage bone disease in patients with kidney problems because of its unique mechanism of action. However, regulatory warnings require that patients with severe renal impairment use the medicine with caution and receive mandatory, regular monitoring of their serum calcium and phosphate levels.

Q: Why do doctors prescribe Cascal instead of other treatments?

The official rationale is that the active component, Alfacalcidol, is a synthetic analogue that bypasses the need for the kidney to perform the final activation step. This mechanism offers a more predictable and controlled effect on mineral metabolism, which may offer a clinical advantage in certain patient populations.

Q: What is the usual duration of effect after taking Cascal?

Pharmacokinetic data indicates that the active form of the medicine is quickly metabolized, having a short elimination half-life. However, the overall pharmacological effect on the body is documented to persist for approximately three to five days following a single dose.

Q: What types of clinical trials were done for Cascal?

The regulatory assessment of Cascal included various types of studies. The research involved Phase 1 trials for pharmacodynamics, Phase 2 trials to identify dose response, and pivotal Phase 3 randomized, placebo-controlled trials to confirm clinical efficacy and safety in broader patient groups.

Q: What is the chemical name for Cascal?

Cascal is a trade name for the combination of two components. The official chemical name for the active ingredient Alfacalcidol is 1-alpha-hydroxycholecalciferol (or 1-alpha-hydroxyvitamin D3). The other component is Calcium Carbonate.

Q: Does Cascal have any specific warnings for people with heart conditions?

Official warnings note that concurrent use with certain heart medications, specifically Digitalis glycosides, is prohibited if the patient has high calcium levels, due to the risk of severe cardiac arrhythmias (irregular heartbeats). High calcium levels themselves can also potentially worsen pre-existing heart disease.

Q: Why is Cascal sometimes stopped suddenly?

Regulatory guidance requires that treatment be stopped immediately if the patient develops hypercalcaemia (high calcium levels). This is a safety measure to prevent prolonged exposure to high calcium concentrations, and the medicine is typically only restarted once levels return to the normal range.

How should Cascal be stored and disposed of?

How to Store and Dispose of Cascal (Alfacalcidol/Calcium Carbonate)

The storage and disposal of Cascal must strictly adhere to regulatory labeling requirements to maintain product stability and safety.

Official Storage Requirements

Condition	Requirement
Temperature	Store at controlled room temperature, not exceeding 25 C (77 F).
Protection	Keep protected from light and moisture; do not freeze.
Packaging	Must remain in the original container and be kept tightly closed.
Child Safety	Store out of the sight and reach of children.

Disposal Instructions

Unused or expired Cascal must not be thrown into wastewater (e.g., flushed down the toilet) or household trash. Regulatory mandates require that the product be disposed of through an authorized pharmaceutical waste collection program (e.g., drug take-back) to comply with local environmental regulations.

Cascal